These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 39339720)

  • 1. Progress in the Study of Animal Models of Metabolic Dysfunction-Associated Steatotic Liver Disease.
    Fu Y; Hua Y; Alam N; Liu E
    Nutrients; 2024 Sep; 16(18):. PubMed ID: 39339720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD).
    Vacca M; Kamzolas I; Harder LM; Oakley F; Trautwein C; Hatting M; Ross T; Bernardo B; Oldenburger A; Hjuler ST; Ksiazek I; Lindén D; Schuppan D; Rodriguez-Cuenca S; Tonini MM; Castañeda TR; Kannt A; Rodrigues CMP; Cockell S; Govaere O; Daly AK; Allison M; Honnens de Lichtenberg K; Kim YO; Lindblom A; Oldham S; Andréasson AC; Schlerman F; Marioneaux J; Sanyal A; Afonso MB; Younes R; Amano Y; Friedman SL; Wang S; Bhattacharya D; Simon E; Paradis V; Burt A; Grypari IM; Davies S; Driessen A; Yashiro H; Pors S; Worm Andersen M; Feigh M; Yunis C; Bedossa P; Stewart M; Cater HL; Wells S; Schattenberg JM; Anstee QM; ; Tiniakos D; Perfield JW; Petsalaki E; Davidsen P; Vidal-Puig A
    Nat Metab; 2024 Jun; 6(6):1178-1196. PubMed ID: 38867022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vitamin D and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Novel Mechanistic Insights.
    Aggeletopoulou I; Tsounis EP; Triantos C
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extracellular Vesicles and Their Correlation with Inflammatory Factors in an Experimental Model of Steatotic Liver Disease Associated with Metabolic Dysfunction.
    Keingeski MB; Longo L; Brum da Silva Nunes V; Figueiró F; Dallemole DR; Pohlmann AR; Vier Schmitz TM; da Costa Lopez PL; Álvares-da-Silva MR; Uribe-Cruz C
    Metab Syndr Relat Disord; 2024 Jun; 22(5):394-401. PubMed ID: 38498801
    [No Abstract]   [Full Text] [Related]  

  • 5. Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD.
    Abdelhameed F; Kite C; Lagojda L; Dallaway A; Chatha KK; Chaggar SS; Dalamaga M; Kassi E; Kyrou I; Randeva HS
    Curr Obes Rep; 2024 Sep; 13(3):510-531. PubMed ID: 38809396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circular RNA RRM2 alleviates metabolic dysfunction-associated steatotic liver disease by targeting miR-142-5p to increase NRG1 expression.
    Wu LF; Zhou ZJ; Zeng YH; Yang SL; Zhang QY
    Am J Physiol Gastrointest Liver Physiol; 2024 Oct; 327(4):G485-G498. PubMed ID: 39259911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of PANoptosis in metabolic dysfunction-associated steatotic liver disease.
    Ni K; Meng L
    Clin Res Hepatol Gastroenterol; 2024 Aug; 48(7):102381. PubMed ID: 38821484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic Ablation of STE20-Type Kinase MST4 Does Not Alleviate Diet-Induced MASLD Susceptibility in Mice.
    Caputo M; Andersson E; Xia Y; Hou W; Cansby E; Erikson M; Lind DE; Hallberg B; Amrutkar M; Mahlapuu M
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic Dysfunction-Associated Steatotic Liver Disease: From Pathogenesis to Current Therapeutic Options.
    Portincasa P; Khalil M; Mahdi L; Perniola V; Idone V; Graziani A; Baffy G; Di Ciaula A
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phytonanotherapy for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease.
    Nendouvhada LP; Sibuyi NRS; Fadaka AO; Meyer S; Madiehe AM; Meyer M; Gabuza KB
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891759
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease.
    Younossi ZM; Paik JM; Stepanova M; Ong J; Alqahtani S; Henry L
    J Hepatol; 2024 May; 80(5):694-701. PubMed ID: 38286339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic-Dysfunction-Associated Steatotic Liver Disease-Its Pathophysiology, Association with Atherosclerosis and Cardiovascular Disease, and Treatments.
    Yanai H; Adachi H; Hakoshima M; Iida S; Katsuyama H
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Type 2 diabetes mellitus and cardiometabolic outcomes in metabolic dysfunction-associated steatotic liver disease population.
    Chew NWS; Pan XH; Chong B; Chandramouli C; Muthiah M; Lam CSP
    Diabetes Res Clin Pract; 2024 May; 211():111652. PubMed ID: 38574897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inflammatory markers as diagnostic and precision nutrition tools for metabolic dysfunction-associated steatotic liver disease: Results from the Fatty Liver in Obesity trial.
    Mogna-Peláez P; Riezu-Boj JI; Milagro FI; Herrero JI; Elorz M; Benito-Boillos A; Tobaruela-Resola AL; Tur JA; Martínez JA; Abete I; Zulet MA
    Clin Nutr; 2024 Jul; 43(7):1770-1781. PubMed ID: 38861890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel fatty acid mimetic with pan-PPAR partial agonist activity inhibits diet-induced obesity and metabolic dysfunction-associated steatotic liver disease.
    Sahin C; Melanson JR; Le Billan F; Magomedova L; Ferreira TAM; Oliveira AS; Pollock-Tahari E; Saikali MF; Cash SB; Woo M; Romeiro LAS; Cummins CL
    Mol Metab; 2024 Jul; 85():101958. PubMed ID: 38763495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Relationship between Pathogenesis and Possible Treatments for the MASLD-Cirrhosis Spectrum.
    Vidal-Cevallos P; Sorroza-Martínez AP; Chávez-Tapia NC; Uribe M; Montalvo-Javé EE; Nuño-Lámbarri N
    Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of Lipid Class Used for Omega-3 Fatty Acid Supplementation on Liver Fat Accumulation in MASLD.
    Sabinari I; Horakova O; Cajka T; Kleinova V; Wieckowski MR; Rossmeisl M
    Physiol Res; 2024 Aug; 73(Suppl 1):S295-S320. PubMed ID: 39016154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The multifaceted roles of B lymphocytes in metabolic dysfunction-associated steatotic liver disease.
    Li H; Xia N
    Front Immunol; 2024; 15():1447391. PubMed ID: 39372417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exercise enhances hepatic mitochondrial structure and function while preventing endoplasmic reticulum stress and metabolic dysfunction-associated steatotic liver disease in mice fed a high-fat diet.
    Souza-Tavares H; Santana-Oliveira DA; Vasques-Monteiro IML; Silva-Veiga FM; Mandarim-de-Lacerda CA; Souza-Mello V
    Nutr Res; 2024 Jun; 126():180-192. PubMed ID: 38759501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring the Regulatory Effect of LPJZ-658 on Copper Deficiency Combined with Sugar-Induced MASLD in Middle-Aged Mice Based on Multi-Omics Analysis.
    Li C; Liu Z; Wei W; Chen C; Zhang L; Wang Y; Zhou B; Liu L; Li X; Zhao C
    Nutrients; 2024 Jun; 16(13):. PubMed ID: 38999758
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.